Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic liver cancer classification: Results of a prospective analysis

Archives of Surgery

Volumn 143, Issue 11, 2008, Pages 1082-1090

  Torzilli, Guido ^a,b   Donadon, Matteo ^a   Marconi, Matteo ^a   Palmisano, Angela ^a   Del Fabbro, Daniele ^a   Spinelli, Antonino ^a   Botea, Florin ^a   Montorsi, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ASCITES; CANCER CLASSIFICATION; CANCER INVASION; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LAPAROTOMY; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FAILURE; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; PNEUMOTHORAX; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; THORACOCENTESIS; TREATMENT OUTCOME; WOUND DEHISCENCE;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SELECTION; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 56549084520     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.143.11.1082     Document Type: Article

References (56)

1. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463-472.
2. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35(3):519-524.
3. Llovet JM, Fuster J, Bruix J; Barcelona-Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10(2)(suppl 1):S115-S120.
4. Marrero JA. Staging systems for hepatocellular carcinoma: should we all use the BCLC system? J Hepatol. 2006;44(4):630-632.
5. Imamura H, Seyama Y, Kokudo N, et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg. 2003;138(11):1198-1206.
6. Torzilli G, Makuuchi M, Inoue K, et al. No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? a prospective analysis of our approach. Arch Surg. 1999;134(9):984-992.
7. Fan ST, Lo CM, Liu CL, et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999;229(3):322-330.
8. Ng KK, Vauthey JN, Pawlik TM, et al; International Cooperative Study Group on Hepatocellular Carcinoma. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? results from a multi-institutional database. Ann Surg Oncol. 2005;12(5):364-373.
9. Minagawa M, Makuuchi M, Takayama T, Ohtomo K. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg. 2001;233(3):379-384.
10. Pawlik TM, Poon RT, Abdalla EK, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery. 2005;137(4):403-410.
11. Ikai I, Yamamoto Y, Yamamoto N, et al. Results of hepatic resection for hepatocellular carcinoma invading major portal and/or hepatic veins. Surg Oncol Clin N Am. 2003;12(1):65-75.
12. Couinaud C. Le Foie: Etude Anatomiques et Chirurgicales. Paris, France: Masson Publishers; 1957.
13. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334(11):693-699.
14. Japanese Research Society for Portal Hypertension. The general rules for recording endoscopic findings on esophageal varices. Jpn J Surg. 1980;10(1):84-87.
15. Torzilli G, Del Fabbro D, Olivari N, Callida F, Montorsi M, Makuuchi M. Contrastenhanced ultrasonography during liver surgery. Br J Surg. 2004;91(9):1165-1167.
16. Torzilli G, Montorsi M, Donadon M, et al. "Radical but conservative" is the main goal for ultrasonography-guided liver resection: prospective validation of this approach. J Am Coll Surg. 2005;201(4):517-528.
17. Torzilli G, Montorsi M, Del Fabbro D, Palmisano A, Donadon M, Makuuchi M. Ultrasonographically guided surgical approach to liver tumours involving the hepatic veins close to the caval confluence. Br J Surg. 2006;93(10):1238-1246.
18. Pringle JH. Notes on the arrest of hepatic hemorrhage due to trauma. Ann Surg. 1908;48(4):541-549.
19. Ijichi M, Takayama T, Toyoda H, Sano K, Kubota K, Makuuchi M. Randomized trial of the usefulness of a bile leakage test during hepatic resection. Arch Surg. 2000;135(12):1395-1400.
20. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48900 necropsies. Cancer. 1954;7(3):462-503.
21. Torzilli G, Olivari N, Del Fabbro D, et al. Bilirubin level fluctuation in drain discharge after hepatectomies justifies long-term drain maintenance. Hepatogastroenterology. 2005;52(64):1206-1210.
22. Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006;44(4):723-731.
23. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208-1236.
24. Schroeder RA, Marroquin CE, Bute BP, Khuri S, Henderson WG, Kuo PC. Predictive indices of morbidity and mortality after liver resection. Ann Surg. 2006; 243(3):373-379.
25. Raut CP, Izzo F, Marra P, et al. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol. 2005;12(8):616-628.
26. Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44(6):1543-1554.
27. Takayasu K, Arii S, Ikai I, et al; Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131(2):461-469.
28. Vetter D, Wenger JJ, Bergier JM, Doffoel M, Bockel R. Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a Western comparative study in 60 patients. Hepatology. 1991; 13(3):427-433.
29. Bronowicki JP, Vetter D, Dumas F, et al. Transcatheter oily chemoembolization for hepatocellular carcinoma: a 4-year study of 127 French patients. Cancer. 1994; 74(1):16-24.
30. Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 1999;229(6):790-799.
31. Belghiti J, Regimbeau JM, Durand F, et al. Resection of hepatocellular carcinoma: a European experience on 328 cases. Hepatogastroenterology. 2002; 49(43):41-46.
32. Teh SH, Christein J, Donohue J, et al. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg. 2005;9(9):1207-1215.
33. Miyagawa S, Makuuchi M, Kawasaki S, Kakazu T. Criteria for safe hepatic resection. Am J Surg. 1995;169(6):589-594.
34. Lau H, Man K, Fan ST, Yu WC, Lo CM, Wong J. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg. 1997;84(9):1255-1259.
35. Redaelli CA, Dufour JF, Wagner M, et al. Preoperative galactose elimination capacity predicts complications and survival after hepatic resection. Ann Surg. 2002; 235(1):77-85.
36. Poon RT, Fan ST. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl. 2004;10(2)(suppl 1):S39-S45.
37. Di Stefano DR, de Baere T, Denys A, et al. Preoperative percutaneous portal vein embolization: evaluation of adverse events in 188 patients. Radiology. 2005; 234(2):625-630.
38. Azoulay D, Castaing D, Smail A, et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg. 2000;231(4):480-486.
39. Elias D, Ouellet JF, De Baere T, Lasser P, Roche A. Preoperative selective portal vein embolization before hepatectomy for liver metastases: long-term results and impact on survival. Surgery. 2002;131(3):294-299.
40. Grazi GL, Ercolani G, Pierangeli F, et al. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg. 2001;234(1):71-78.
41. Makuuchi M, Takayama T, Gunven P, Kosuge T, Yamazaki S, Hasegawa H. Restrictive versus liberal blood transfusion policy for hepatectomies in cirrhotic patients. World J Surg. 1989;13(5):644-648.
42. Torzilli G, Gambetti A, Del Fabbro D, et al. Techniques for hepatectomies without blood transfusion focusing on interpretation of postoperative anemia. Arch Surg. 2004;139(10):1061-1065.
43. Capussotti L, Ferrero A, Vigano L, Muratore A, Polastri R, Bouzari H. Portal hypertension: contraindication to liver surgery? World J Surg. 2006;30(6):992-999.
44. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999; 30(6):1434-1440.
45. Keiding S, Vilstrup H. Intrahepatic heterogeneity of hepatic venous pressure gradient in human cirrhosis. Scand J Gastroenterol. 2002;37(8):960-964.
46. Wadhawan M, Dubey S, Sharma BC, Sarin SK, Sarin SK. Hepatic venous pressure gradient in cirrhosis: correlation with the size of varices, bleeding, ascites, and Child's status. Dig Dis Sci. 2006;51(12):2264-2269.
47. Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol. 2006;16(3):661-669.
48. Molinari M, Kachura JR, Dixon E, et al. Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre. R Coll Radio Clin Oncol. 2006;18(9):684-692.
49. Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol. 2006;33(4):392-406.
50. Yoon SS, Kim SH, Gonen M, et al. Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases. Ann Surg Oncol. 2006;13(3):353-362.
51. Torzilli G, Palmisano A, Del Fabbro D, et al. Contrast-enhanced intraoperative ultrasonography during surgery for hepatocellular carcinoma in liver cirrhosis: is it useful or useless? a prospective cohort study of our experience. Ann Surg Oncol. 2007;14(4):1347-1355.
52. Poon RT, Fan ST, Ng IO, Wong J. Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg. 2000;231 (4):544-551.
53. Ochiai T, Takayama T, Inoue K, et al. Hepatic resection with and without surgical margins for hepatocellular carcinoma in patients with impaired liver function. Hepatogastroenterology. 1999;46(27):1885-1889.
54. Shi M, Guo RP, Lin XJ, et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg. 2007;245(1):36-43.
55. Matsui Y, Terakawa N, Satoi S, et al. Postoperative outcomes in patients with hepatocellular carcinomas resected with exposure of the tumor surface: clinical role of the no-margin resection. Arch Surg. 2007;142(7):596-602.
56. Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981;305(1):6-11.